Xintela AB (OSTO:XINT) Total Equity : kr-7.70 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Xintela AB Total Equity?

Xintela AB's total equity for the quarter that ended in Mar. 2024 was kr-7.70 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Xintela AB Total Equity Historical Data

The historical data trend for Xintela AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xintela AB Total Equity Chart

Xintela AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

9.32

27.61

2.51

5.78

4.38

Xintela AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Equity	Get a 7-Day Free Trial															-10.55	-28.62	8.41	4.38	-7.70

Xintela AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Xintela AB's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	18.395	-	14.015
	=	4.38

Xintela AB's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2024 )	-	Total Liabilities(Q: Mar. 2024 )
	=	22.084	-	29.786
	=	-7.70

Xintela AB Total Equity Related Terms

Thank you for viewing the detailed overview of Xintela AB's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Xintela AB (OSTO:XINT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Medicon Village, Lund, SWE, 22381

Website

http://www.xintela.se

Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.

Xintela AB (OSTO:XINT) Headlines

No Headlines